Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -74.75% is 84% above its 5-year average of -457.23%, near the high end of its 5-year range (-1861.60%–57.37%).
89.26% above its 12-month average of -696.01%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1269.64%.
NET PROFIT MARGIN
-74.75%
NET PROFIT MARGIN AVG TTM
-696.01%
NET PROFIT MARGIN AVG 3Y
-564.35%
NET PROFIT MARGIN AVG 5Y
-457.23%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+89.26%
CURRENT VS 3Y AVG
+86.75%
CURRENT VS 5Y AVG
+83.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
IDEAYA Biosciences, Inc.
Market Cap
$3.47B
Net Profit Margin
-74.75%
TTM Avg
-696.01%
3Y Avg
-564.35%
5Y Avg
-457.23%
Market Cap
$3.42B
Net Profit Margin
33.42%
TTM Avg
30.07%
3Y Avg
2.48%
5Y Avg
-14.75%
Market Cap
$3.53B
Net Profit Margin
-1.69%
TTM Avg
-12.55%
3Y Avg
-19.61%
5Y Avg
-21.06%
Market Cap
$3.05B
Net Profit Margin
6.15%
TTM Avg
-37.77%
3Y Avg
-2241.27%
5Y Avg
-1494.18%
Market Cap
$3.03B
Net Profit Margin
-14191.20%
TTM Avg
0.00%
3Y Avg
-86.13%
5Y Avg
-153.41%
Market Cap
$3.02B
Net Profit Margin
0.00%
TTM Avg
-172.68%
3Y Avg
-306.20%
5Y Avg
-1288.24%
Market Cap
$3.96B
Net Profit Margin
1.39%
TTM Avg
-2.46%
3Y Avg
-2.37%
5Y Avg
0.86%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | $3.47B | -74.75% | -696.01% | -564.35% | -457.23% |
| Celcuity Inc. (CELC)vs › | $3.45B | 0.00% | 0.00% | 0.00% | 0.00% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.42B | 33.42% | 30.07% | 2.48% | -14.75% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | -1.69% | -12.55% | -19.61% | -21.06% |
| CareDx, Inc (CDNA)vs › | $3.39B | 24.23% | 5.06% | -20.39% | -16.94% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.05B | 6.15% | -37.77% | -2241.27% | -1494.18% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.03B | -14191.20% | 0.00% | -86.13% | -153.41% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.02B | 0.00% | -172.68% | -306.20% | -1288.24% |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | 1.39% | -2.46% | -2.37% | 0.86% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.96B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-72.8%
Net Profit Margin
-74.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1269.64% |
| 2026-03-31 | -1502.12% |
| 2025-12-31 | -765.66% |
| 2025-09-30 | 57.37% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | -1861.60% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -865.54% |
| 2023-09-30 | -341.38% |
| 2023-06-30 | -787.98% |
| 2023-03-31 | -300.00% |
| 2022-12-31 | -601.72% |
| 2022-09-30 | 5.44% |
| 2022-06-30 | -376.96% |
| 2022-03-31 | -123.36% |
| 2021-12-31 | -614.65% |
| 2021-09-30 | -129.03% |
| 2021-06-30 | -125.02% |
| 2021-03-31 | -124.48% |
| 2020-12-31 | -48.58% |
| 2020-09-30 | -54.93% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
